Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Chubb
Moodys
Federal Trade Commission
Cerilliant
Colorcon
Express Scripts
Merck

Generated: April 22, 2018

DrugPatentWatch Database Preview

ADAPALENE Drug Profile

« Back to Dashboard

When do Adapalene patents expire, and what generic alternatives are available?

Adapalene is a drug marketed by Fougera Pharms, Actavis Mid Atlantic, Glenmark Generics, Pliva Hrvatska Doo, Taro, Tolmar, Call Inc, and Perrigo Israel. and is included in eleven NDAs.

The generic ingredient in ADAPALENE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Five suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.
Drug patent expirations by year for ADAPALENE
Pharmacology for ADAPALENE
Ingredient-typeRetinoids
Drug ClassRetinoid
Synonyms for ADAPALENE
(non-d)Adapalene-d15
106685-40-9
1L4806J2QF
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo(3.3.1.1(sup 3,7))dec-1-ylphenyl)-
2-Naphthalenecarboxylic acid, 6-(4-methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-
4CA-0111
6-(3-((3r,5r,7r)-adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(1-Adamantyl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-(Adamantan-1-yl)-4-methoxyphenyl)-2-naphthoic acid
6-(3-Adamantan-1-yl-4-methoxy-phenyl)-naphthalene-2-carboxylic acid
6-(3-adamantan-1-yl-4-methoxyphenyl)naphthalene-2-carboxylic acid
6-(4-Methoxy-3-tricyclo[3.3.1.13,7]dec-1-ylphenyl)-2-naphthalenecarboxylic acid
6-[3-(1-adamantyl)-4-methoxy-phenyl]naphthalene-2-carboxylic acid
6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHALENE CARBOXYLIC ACID
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalene-carboxylic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthalenecarboxylic acid
6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(1-adamantyl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]-2-naphthoic acid
6-[3-(adamantan-1-yl)-4-methoxyphenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.1~3,7~]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
6-[4-methoxy-3-(tricyclo[3.3.1.13,7]dec-1-yl)phenyl]naphthalene-2-carboxylic acid
685A409
A801483
AB0013899
AB01274764_03
AB01274764_04
AB01274764-01
AB01274764-02
AB13763
AB2000023
ABP000590
AC-1974
AC1L1SOH
AC1Q5USH
Adaferin
Adaferin (TN)
Adapalen
Adapalene (JAN/USAN/INN)
Adapalene [USAN:BAN:INN]
Adapalene [USAN:INN:BAN]
Adapalene for peak identification, European Pharmacopoeia (EP) Reference Standard
Adapalene, >=98% (HPLC)
Adapalene, European Pharmacopoeia (EP) Reference Standard
Adapalene, pharmaceutical secondary standard; traceable to USP and PhEur
Adapalene, United States Pharmacopeia (USP) Reference Standard
Adapalene/
Adapaleno
Adapaleno [INN-Spanish]
Adapalenum
Adapalenum [INN-Latin]
AJ-45604
AK-72900
AKOS005145841
AKOS015895391
Ambap106685-40-9
AN-593
AOB6389
API0001385
BC205779
BCP9000231
BDBM50048280
BIDD:GT0264
BR-72900
BRD-K33127281-001-01-5
C28H28O3
CAS-106685-40-9
CCG-213060
CCG-221237
CD 271
CD-271
CD271
CHEBI:31174
CHEMBL1265
CHEMBL76401
CPD000466349
CS-1789
CTK8E8906
D01112
D0JC9N
DB00210
Differin
Differin (TN)
Differin Gel
Differin Gel 0.1%
Differin, Adapalene
Differin, Teva, Pimpal, Gallet, Adelene, Adeferin
Differine
DR002478
DSSTox_CID_26481
DSSTox_GSID_46481
DSSTox_RID_81652
DTXSID5046481
EBD19549
F2173-0588
FT-0631040
GTPL5429
HMS3264F15
HMS3654F11
HY-B0091
I06-0642
I810
KB-246947
KS-000002B5
KS-1196
LS-172017
LZCDAPDGXCYOEH-UHFFFAOYSA-N
MFCD03106112
MLS000759463
MLS006010036
MolPort-003-986-211
NAP030
NCGC00164617-01
NCGC00164617-02
NCGC00164617-04
NCGC00164617-05
PL029988
PL040836
RTR-001330
S-3513
s1276
SAM001246663
SC-17327
SCHEMBL2747
SMR000466349
SMR002529673
SR-01000942194
SR-01000942194-2
ST2412159
STL453114
TL8000241
Tox21_112236
Tox21_112236_1
TR-001330
UNII-1L4806J2QF
ZINC3784182

US Patents and Regulatory Information for ADAPALENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Fougera Pharms ADAPALENE adapalene CREAM;TOPICAL 090824-001 Jun 30, 2010 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Call Inc ADAPALENE adapalene SOLUTION;TOPICAL 203981-001 Sep 23, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Pliva Hrvatska Doo ADAPALENE adapalene GEL;TOPICAL 090962-001 Jun 2, 2010 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Call Inc ADAPALENE adapalene SOLUTION;TOPICAL 204593-001 Jan 5, 2016 AB RX No Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chubb
Medtronic
Dow
Cerilliant
Johnson and Johnson
Argus Health
Queensland Health
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.